IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-32486-8.html
   My bibliography  Save this article

A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy

Author

Listed:
  • Brian D. Ross

    (University of Michigan School of Medicine
    University of Michigan School of Medicine)

  • Youngsoon Jang

    (University of Michigan School of Medicine)

  • Amanda Welton

    (University of Michigan School of Medicine)

  • Christopher A. Bonham

    (University of Michigan School of Medicine)

  • Dilrukshika S. W. Palagama

    (University of Michigan School of Medicine)

  • Kevin Heist

    (University of Michigan School of Medicine)

  • Jagadish Boppisetti

    (University of Michigan School of Medicine)

  • Kasun P. Imaduwage

    (University of Michigan School of Medicine)

  • Tanner Robison

    (University of Michigan School of Medicine
    University of Michigan)

  • Leah R. King

    (University of Michigan School of Medicine)

  • Edward Z. Zhang

    (University of Michigan School of Medicine)

  • Cyrus Amirfazli

    (University of Michigan School of Medicine)

  • Kathryn E. Luker

    (University of Michigan School of Medicine)

  • Winston Y. Lee

    (University of Michigan School of Medicine)

  • Gary D. Luker

    (University of Michigan School of Medicine
    University of Michigan School of Medicine)

  • Thomas L. Chenevert

    (University of Michigan School of Medicine)

  • Marcian E. Van Dort

    (University of Michigan School of Medicine)

Abstract

Activation of compensatory signaling nodes in cancer often requires combination therapies that are frequently plagued by dose-limiting toxicities. Intestinal lymphatic drug absorption is seldom explored, although reduced toxicity and sustained drug levels would be anticipated to improve systemic bioavailability. A potent orally bioavailable multi-functional kinase inhibitor (LP-182) is described with intrinsic lymphatic partitioning for the combined targeting of phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling pathways without observable toxicity. We demonstrate selectivity and therapeutic efficacy through reduction of downstream kinase activation, amelioration of disease phenotypes, and improved survival in animal models of myelofibrosis. Our further characterization of synthetic and physiochemical properties for small molecule lymphatic uptake will support continued advancements in lymphatropic therapy for altering disease trajectories of a myriad of human disease indications.

Suggested Citation

  • Brian D. Ross & Youngsoon Jang & Amanda Welton & Christopher A. Bonham & Dilrukshika S. W. Palagama & Kevin Heist & Jagadish Boppisetti & Kasun P. Imaduwage & Tanner Robison & Leah R. King & Edward Z., 2022. "A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
  • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32486-8
    DOI: 10.1038/s41467-022-32486-8
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-32486-8
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-022-32486-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Haijuan Yang & Derek G. Rudge & Joseph D. Koos & Bhamini Vaidialingam & Hyo J. Yang & Nikola P. Pavletich, 2013. "mTOR kinase structure, mechanism and regulation," Nature, Nature, vol. 497(7448), pages 217-223, May.
    2. Haipeng Liu & Kelly D. Moynihan & Yiran Zheng & Gregory L. Szeto & Adrienne V. Li & Bonnie Huang & Debra S. Van Egeren & Clara Park & Darrell J. Irvine, 2014. "Structure-based programming of lymph-node targeting in molecular vaccines," Nature, Nature, vol. 507(7493), pages 519-522, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jia He & Chaoyu Wang & Xiao Fang & Junyao Li & Xueying Shen & Junxia Zhang & Cheng Peng & Hongjian Li & Sai Li & Jeffrey M. Karp & Rui Kuai, 2024. "Tuning the fluidity and protein corona of ultrasound-responsive liposomal nanovaccines to program T cell immunity in mice," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    2. Ling Wang & Lei Chen & Zhihong Liu & Minghao Zheng & Qiong Gu & Jun Xu, 2014. "Predicting mTOR Inhibitors with a Classifier Using Recursive Partitioning and Naïve Bayesian Approaches," PLOS ONE, Public Library of Science, vol. 9(5), pages 1-15, May.
    3. Ella N. Hoogenboezem & Shrusti S. Patel & Justin H. Lo & Ashley B. Cavnar & Lauren M. Babb & Nora Francini & Eva F. Gbur & Prarthana Patil & Juan M. Colazo & Danielle L. Michell & Violeta M. Sanchez &, 2024. "Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    4. Shenqiang Wang & Ying Zhang & Yanfang Wang & Yinxian Yang & Sheng Zhao & Tao Sheng & Yuqi Zhang & Zhen Gu & Jinqiang Wang & Jicheng Yu, 2023. "An in situ dual-anchoring strategy for enhanced immobilization of PD-L1 to treat autoimmune diseases," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    5. Vijayendra Dasari & Lisa K. McNeil & Kirrilee Beckett & Matthew Solomon & George Ambalathingal & T. Le Thuy & Archana Panikkar & Caitlyn Smith & Martin P. Steinbuck & Aniela Jakubowski & Lochana M. Se, 2023. "Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    6. Vasiliki Karalis & Franklin Caval-Holme & Helen S. Bateup, 2022. "Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex," Nature Communications, Nature, vol. 13(1), pages 1-20, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32486-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.